A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Fiche publication
Date publication
septembre 2019
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Mme LAHEURTE Caroline
Tous les auteurs :
Teixeira L, Medioni J, Garibal J, Adotévi O, Doucet L, Dragon Durey MA, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard SM, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P
Lien Pubmed
Résumé
Human telomerase reverse transcriptase (hTERT) is highly expressed in >85% of human tumors and is thus considered as a good tumor-associated antigen candidate for vaccine development. We conducted a phase I study to investigate the safety, tolerability, clinical response and immunogenicity of INVAC-1, a DNA plasmid encoding a modified hTERT protein in patients with relapsed or refractory solid tumors.
Référence
Clin. Cancer Res.. 2019 Sep 26;: